WallStSmart

LENZ Therapeutics Inc (LENZ)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

LENZ Therapeutics Inc generates 2729% more annual revenue ($20.99M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. LENZ earns a higher WallStSmart Score of 31/100 (F).

LENZ

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 7.16

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LENZ3 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.1610/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

LENZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$181.54M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LENZ

The strongest argument for LENZ centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : LENZ

The primary concerns for LENZ are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

LENZ carries more volatility with a beta of 1.47 — expect wider price swings.

LENZ is growing revenue faster at 0.0% — sustainability is the question.

LENZ generates stronger free cash flow (-34M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LENZ scores higher overall (31/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

LENZ Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

LENZ Therapeutics Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for neurological disorders, with an emphasis on addressing significant unmet needs in the central nervous system (CNS). Leveraging advanced drug formulation and delivery technologies, the company boasts a robust pipeline of proprietary assets designed to improve patient outcomes. With strategic partnerships and a strong commitment to rigorous clinical research, LENZ is well-positioned for substantial growth and aims to establish itself as a key player in the biopharmaceutical sector, capitalizing on emerging opportunities within the evolving healthcare market.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?